United States Cardiac Arrest Treatment Market Accelerated by Growing Out-of-Hospital Incidents & Innovation in Defibrillator Technology | Key Players: ZOLL Medical Corporation, GE Healthcare, Stryker, Boston Scientific Corporation, Cardiac Science Corpora

Global Cardiac Arrest Treatment Market size was valued at US$ 16,230 million in 2021 and is estimated to reach US$ 24,690 million by 2031, growing at a CAGR of 9.21% during the forecast period 2024-2031.

The cardiac arrest treatment market focuses on developing, producing, and distributing interventions for managing and reversing cardiac arrest, a condition where heart function ceases, affecting blood circulation to vital organs. It is driven by the growing prevalence of cardiovascular diseases, advancements in medical technology, and an aging population. Treatment options include medications like vasopressors and devices such as defibrillators, with hospitals serving as the primary distribution channel. While North America leads due to its advanced healthcare systems, the Asia-Pacific region is seeing rapid growth thanks to rising healthcare investments. However, challenges such as high treatment costs and limited access in low-resource regions persist, although innovations continue to improve treatment outcomes.

Sample Request to Evaluate M&A and Licensing Opportunities in Cardiac Arrest Treatment Market: https://www.datamintelligence.com/download-sample/cardiac-arrest-treatment-market?ophp

In the U.S., more than 640,000 people suffer a cardiac arrest each year, with about 350,000 of those occurring outside hospitals. Survival rates remain low around 10% for out-of‐hospital cases and ~25% for in-hospital arrests. Advances in device tech especially defibrillators and wearable/implantable options and increasing public awareness (CPR training, AED placements) are driving demand for better treatment and earlier response. Meanwhile, the U.S. defibrillator market is growing strongly, bolstered by both hospital and public-access segments pushing for wider availability and improved designs.

Market Growth Drivers

Increasing sedentary lifestyles are expected to contribute to the market's growth.

The growing prevalence of sedentary lifestyles is expected to drive significant growth in the market. According to the World Health Organization, a lack of physical activity is a major global health issue, being the fourth leading cause of death worldwide. Every year, around 3.2 million deaths and 32.1 million years of healthy life are lost due to insufficient physical activity, which accounts for about 2.1% of global health issues. People who don't engage in regular physical activity have a 20% to 30% higher risk of mortality from any cause compared to those who get at least 30 minutes of moderate exercise most days of the week. This widespread inactivity among adults, defined as less than 150 minutes of moderate-intensity exercise per week, is contributing to the rising health risks globally.

For Instant, on August 29, 2022, Bayer revealed that Kerendia reduced the incidence of sudden cardiac death in a wide range of patients with early to late-stage chronic kidney disease (CKD) and diabetes. This finding came from a prespecified, pooled analysis of specific patients from the Fidelio-DKD and Figaro-DKD studies. Although Kerendia did not reach statistical significance in reducing all-cause and cardiovascular mortality across the entire study population, a targeted analysis of patients with CKD and type 2 diabetes showed more promising results for the drug.

Market Segmentation

By Treatment Type the market is sub segmented into Drugs BetaBlockers, Vasopressors, Anti-Arrhythmic Drugs, Anticholinergic Drugs, Corticosteroids, Fibrinolytic Drugs, and Others
By Medical Devices the market is classified into Defibrillators, Cardiac Resynchronization Therapy, and Others
By Distribution Channel the market is divided into Hospitals, Independent Pharmacies, and others

Customize Your Scope: https://www.datamintelligence.com/customize/cardiac-arrest-treatment-market?ophp

Regional Outlook

North America region holds the largest market share of the global cardiac arrest treatment market
The Cardiac Arrest Treatment Market in North America is experiencing significant growth, driven by advanced healthcare infrastructure, high levels of healthcare expenditure, and a well-established medical technology sector. The region is headquarter to some of the world's leading hospitals, research institutions, and healthcare providers, which are crucial in driving innovations and the adoption of advanced cardiac arrest treatments such as defibrillators, vasopressors, and cardiac resynchronization therapy devices.

Market Players:

• Koninklijke Philips N.V.
• ZOLL Medical Corporation
• GE Healthcare
• Stryker
• Boston Scientific Corporation
• Cardiac Science Corporation (Aurora Capital Group)
• Bristol-Myers Squibb Company
• Abbott

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.